OncoSec Medical (NSDQ:ONCS) said today that it won Fast Track Designation from the FDA for its ImmunoPulse IL-12 electroporation gene therapy for the treatment of metastatic melanoma.
The biotech company’s electroporation device is designed to locally deliver DNA-based interleukin-12 to stimulate the immune system and fight off cancer cells. The ImmunoPulse device delivers a sequence of short-duration electrical pulses to increase the cancer cell membrane’s permeability and more efficiently deliver the IL-12 gene therapy.
Get the full story at our sister site, Drug Delivery Business News.